Synergistic effect of eravacycline combined with fluconazole against resistant Candida albicans in vitro and in vivo

References

• Wambaugh MA, Denham ST, Ayala M, et al. Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections. Elife. 2020;9: doi: 10.7554/eLife.54160
   PubMed Web of Science ®Google Scholar
• WHO. WHO fungal priority pathogens list to guide research, development and public health action. World Health Organization; 2022.
   Google Scholar
• Amorim-Vaz S, Tran Vdu T, Pradervand S, et al. RNA enrichment method for quantitative transcriptional analysis of pathogens in vivo applied to the fungus Candida albicans. MBio. 2015;6(5):e00942–00915. doi: 10.1128/mBio.00942-15
   PubMed Web of Science ®Google Scholar
• Poulain PD. Candida albicans, plasticity and pathogenesis. Crit Rev Microbiol. 2015;41(2):208–217. doi: 10.3109/1040841X.2013.813904
   PubMed Web of Science ®Google Scholar
• Tadec L, Talarmin JP, Gastinne T, et al. Epidemiology, risk factor, species distribution, antifungal resistance and outcome of candidemia at a single French hospital: a 7-year study. Mycoses. 2016;59(5):296–303. doi: 10.1111/myc.12470
   PubMed Web of Science ®Google Scholar
• Lohse MB, Gulati M, Johnson AD, et al. Development and regulation of single- and multi-species Candida albicans biofilms. Nat Rev Microbiol. 2018;16(1):19–31. doi: 10.1038/nrmicro.2017.107
   PubMed Web of Science ®Google Scholar
• WHO. Antimicrobial resistance: global report on surveillance. WHO, Geneva Switzerland. 2014.
   Google Scholar
• Suchodolski J, Krasowska A. Fructose induces fluconazole resistance in Candida albicans through activation of Mdr1 and Cdr1 transporters. Int J Mol Sci. 2021;22(4):2127. doi: 10.3390/ijms22042127
   PubMed Web of Science ®Google Scholar
• Li X, Zhang N, Zhang L, et al. Synergy and mechanism of leflunomide plus fluconazole against resistant Candida albicans: an in vitro study. Infect Drug Resist. 2023;16:4147–4158. doi: 10.2147/IDR.S415229
   PubMed Web of Science ®Google Scholar
• Saadeh HA, Mubarak MS. Hybrid drugs as potential combatants against drug-resistant microbes: a review. Curr Top Med Chem. 2017;17(8):895–906. doi: 10.2174/1568026616666160927155251
   PubMed Web of Science ®Google Scholar
• Chen X, Ren B, Chen M, et al. NLLSS: predicting synergistic drug combinations based on semi-supervised learning. PLoS Comput Biol. 2016;12(7):e1004975. doi: 10.1371/journal.pcbi.1004975
   PubMed Web of Science ®Google Scholar
• Gao L, Sun Y, Yuan M, et al. In vitro and in vivo study on the synergistic effect of minocycline and azoles against pathogenic fungi. Antimicrob Agents Chemother. 2020;64(6): doi: 10.1128/AAC.00290-20
   Web of Science ®Google Scholar
• Gao Y, Zhang Z, Lun Z, et al. Synergistic effects of fluconazole combined with doxycycline against dual-species cultures of Candida albicans and Staphylococcus epidermidis and the mechanisms of action. Microb Drug Resist. 2022;28(5):525–535. doi: 10.1089/mdr.2021.0301
   PubMed Web of Science ®Google Scholar
• Alosaimy S, Abdul-Mutakabbir JC, Kebriaei R, et al. Evaluation of Eravacycline: a novel fluorocycline. Pharmacotherapy. 2020;40(3):221–238. doi: 10.1002/phar.2366
   PubMed Web of Science ®Google Scholar
• CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts. Wayne, PA: Clinical and Laboratory Standards Institute; 2017. p. M27–Ed4.
   Google Scholar
• Savage KA, Parquet MC, Allan DS, et al. Iron restriction to clinical isolates of Candida albicans by the novel chelator DIBI inhibits growth and increases sensitivity to azoles in vitro and in vivo in a murine model of experimental vaginitis. Antimicrob Agents Chemother. 2018;62(8): doi: 10.1128/AAC.02576-17
   PubMed Web of Science ®Google Scholar
• Tobudic S, Kratzer C, Lassnigg A, et al. In vitro activity of antifungal combinations against Candida albicans biofilms. J Antimicrob Chemother. 2010;65(2):271–274. doi: 10.1093/jac/dkp429
   PubMed Web of Science ®Google Scholar
• Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52(1):1. doi: 10.1093/jac/dkg301
   PubMed Web of Science ®Google Scholar
• Li X, Wu X, Gao Y, et al. Synergistic effects and mechanisms of combined treatment with harmine hydrochloride and azoles for resistant Candida albicans. Front Microbiol. 2019;10:2295. doi: 10.3389/fmicb.2019.02295
   PubMed Web of Science ®Google Scholar
• Ge L, Liu S, Xie L, et al. Differential mRNA expression profiling of oral squamous cell carcinoma by high-throughput RNA sequencing. J Biomed Res. 2015;29(5):397–404. doi: 10.7555/JBR.29.20140088
   PubMedGoogle Scholar
• El Zakhem A, Mahmoud O, Zakhour J, et al. The impact of COVID-19 on the epidemiology and outcomes of candidemia: a retrospective study from a tertiary Care center in Lebanon. J Fungi (Basel). 2023;9(7):769.
   PubMedGoogle Scholar
• Routsi C, Meletiadis J, Charitidou E, et al. Epidemiology of candidemia and fluconazole resistance in an ICU before and during the COVID-19 pandemic Era. Antibiotics. 2022;11(6):771. doi: 10.3390/antibiotics11060771
   Google Scholar
• Szekely J, Rakchang W, Rattanaphan P, et al. Fluconazole and echinocandin resistance of Candida species in invasive candidiasis at a university hospital during pre-COVID-19 and the COVID-19 outbreak. Epidemiol Infect. 2023;151:e146. doi: 10.1017/S0950268823001346
   PubMed Web of Science ®Google Scholar
• Fernandes KE, Weeks K, Carter DA. Lactoferrin is broadly active against yeasts and highly synergistic with Amphotericin B. Antimicrob Agents Chemother. 2020;64(5). doi: 10.1128/AAC.02284-19
   Web of Science ®Google Scholar
• Trevijano-Contador N, Herrero-Fernandez I, Garcia-Barbazan I, et al. Cryptococcus neoformans induces antimicrobial responses and behaves as a facultative intracellular pathogen in the non mammalian model Galleria mellonella. Virulence. 2015;6(1):66–74. doi: 10.4161/21505594.2014.986412
   PubMed Web of Science ®Google Scholar
• Li H, Zhang C, Liu P, et al. In vitro interactions between fluconazole and minocycline against mixed cultures of Candida albicans and staphylococcus aureus. J Microbiol Immunol Infect. 2015;48(6):655–661. doi: 10.1016/j.jmii.2014.03.010
   PubMedGoogle Scholar
• Shi W, Chen Z, Chen X, et al. The combination of minocycline and fluconazole causes synergistic growth inhibition against Candida albicans: an in vitro interaction of antifungal and antibacterial agents. FEMS Yeast Res. 2010;10(7):885–893. doi: 10.1111/j.1567-1364.2010.00664.x
   PubMed Web of Science ®Google Scholar
• Legrand M, Chan CL, Jauert PA, et al. Role of DNA mismatch repair and double-strand break repair in genome stability and antifungal drug resistance in Candida albicans. Eukaryot Cell. 2007;6(12):2194–2205. doi: 10.1128/EC.00299-07
   PubMedGoogle Scholar
• Chauhan N, Visram M, Cristobal-Sarramian A, et al. Morphogenesis checkpoint kinase Swe1 is the executor of lipolysis-dependent cell-cycle progression. Proc Natl Acad Sci U S A. 2015;112(10):E1077–1085. doi: 10.1073/pnas.1423175112
   PubMed Web of Science ®Google Scholar
• O’Sullivan JM, Mihr MJ, Santos MA, et al. The Candida albicans gene encoding the cytoplasmic leucyl-tRNA synthetase: implications for the evolution of CUG codon reassignment. Gene. 2001;275(1):133–140. doi: 10.1016/S0378-1119(01)00632-1
   PubMed Web of Science ®Google Scholar
• Wightman R, Bates S, Amornrrattanapan P, et al. In Candida albicans, the Nim1 kinases Gin4 and Hsl1 negatively regulate pseudohypha formation and Gin4 also controls septin organization. J Cell Bio. 2004;164(4):581–591. doi: 10.1083/jcb.200307176
   PubMed Web of Science ®Google Scholar
• Vidan S, Mitchell AP. Stimulation of yeast meiotic gene expression by the glucose-repressible protein kinase Rim15p. Mol Cell Biol. 1997;17(5):2688–2697. doi: 10.1128/MCB.17.5.2688
   PubMed Web of Science ®Google Scholar
• Das S, Bhuyan R, Goswami AM, et al. Kinome analyses of Candida albicans, C. parapsilosis and C. tropicalis enable novel kinases as therapeutic drug targets in candidiasis. Gene. 2021;780:145530. doi: 10.1016/j.gene.2021.145530
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Sagar N, Hirschi KD. Overexpression of Erg11p by the regulatable GAL1 promoter confers fluconazole resistance in Saccharomyces cerevisiae. Antimicrob Agents Chemother. 1999;43(11):2798–2800. doi: 10.1128/AAC.43.11.2798
   PubMed Web of Science ®Google Scholar
• Martinez-Gomariz M, Perumal P, Mekala S, et al. Proteomic analysis of cytoplasmic and surface proteins from yeast cells, hyphae, and biofilms of Candida albicans. Proteomics. 2009;9(8):2230–2252. doi: 10.1002/pmic.200700594
   PubMed Web of Science ®Google Scholar
• Chiang LY, Sheppard DC, Bruno VM, et al. Candida albicans protein kinase CK2 governs virulence during oropharyngeal candidiasis. Cell Microbiol. 2007;9(1):233–245. doi: 10.1111/j.1462-5822.2006.00784.x
   PubMed Web of Science ®Google Scholar
• Umeyama T, Kaneko A, Nagai Y, et al. Candida albicans protein kinase CaHsl1p regulates cell elongation and virulence. Mol Microbiol. 2005;55(2):381–395. doi: 10.1111/j.1365-2958.2004.04405.x
   PubMed Web of Science ®Google Scholar
• Nett JE, Lepak AJ, Marchillo K, et al. Time course global gene expression analysis of an in vivo Candida biofilm. J Infect Dis. 2009;200(2):307–313. doi: 10.1086/599838
   PubMed Web of Science ®Google Scholar
• Gale CA, Leonard MD, Finley KR, et al. SLA2 mutations cause SWE1-mediated cell cycle phenotypes in Candida albicans and Saccharomyces cerevisiae. Microbiology (Reading). 2009;155(Pt 12):3847–3859. doi: 10.1099/mic.0.033233-0
   PubMedGoogle Scholar